Menin inhibitors are emerging therapeutic agents under clinical investigation in NPM1-mutated and KMT2Ar AML, with a promising effect on the transcriptional network driving leukemogenesis [24]. The gene discussed is MEN1; the disease is acute myeloid leukemia.